Bioventus Capex Per Share from 2010 to 2024

BVS Stock  USD 12.29  0.02  0.16%   
Bioventus Capex Per Share yearly trend continues to be comparatively stable with very little volatility. Capex Per Share is likely to outpace its year average in 2024. From the period from 2010 to 2024, Bioventus Capex Per Share quarterly data regression had r-value of  0.20 and coefficient of variation of  54.66. View All Fundamentals
 
Capex Per Share  
First Reported
2010-12-31
Previous Quarter
0.11751456
Current Value
0.21
Quarterly Volatility
0.08897595
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bioventus financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bioventus' main balance sheet or income statement drivers, such as Depreciation And Amortization of 40.7 M, Interest Expense of 42.7 M or Total Revenue of 386.8 M, as well as many indicators such as Price To Sales Ratio of 0.61, Dividend Yield of 4.0E-4 or PTB Ratio of 1.81. Bioventus financial statements analysis is a perfect complement when working with Bioventus Valuation or Volatility modules.
  
Check out the analysis of Bioventus Correlation against competitors.
For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.

Latest Bioventus' Capex Per Share Growth Pattern

Below is the plot of the Capex Per Share of Bioventus over the last few years. It is Bioventus' Capex Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bioventus' overall financial position and show how it may be relating to other accounts over time.
Capex Per Share10 Years Trend
Pretty Stable
   Capex Per Share   
       Timeline  

Bioventus Capex Per Share Regression Statistics

Arithmetic Mean0.16
Geometric Mean0.15
Coefficient Of Variation54.66
Mean Deviation0.06
Median0.12
Standard Deviation0.09
Sample Variance0.01
Range0.2655
R-Value0.20
Mean Square Error0.01
R-Squared0.04
Significance0.49
Slope0
Total Sum of Squares0.11

Bioventus Capex Per Share History

2024 0.21
2022 0.19
2021 0.12
2020 0.36
2019 0.15
2015 0.13
2014 0.37

About Bioventus Financial Statements

Bioventus shareholders use historical fundamental indicators, such as Capex Per Share, to determine how well the company is positioned to perform in the future. Although Bioventus investors may analyze each financial statement separately, they are all interrelated. The changes in Bioventus' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bioventus' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capex Per Share 0.12  0.21 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bioventus Stock Analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.